Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Hanauer

Showing results (131-140 of 142) with videos related to

Pageof 15
Sort By:
The New England Journal of Medicine|May 6, 1999
Infliximab for the treatment of fistulas in patients with Crohn's diseaseD H Present, P Rutgeerts, S Targan, et al.
Gastroenterology|October 31, 1998
American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12S R Brant, Y Fu, C T Fields, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2005
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's diseaseB G Feagan, W J Sandborn, J P Baker, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2017
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitisJ-F Colombel, W J Sandborn, W Reinisch, et al.
Gut|April 1, 1997
Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trialR I Breuer, K H Soergel, B A Lashner, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trialW J Sandborn, B E Sands, D C Wolf, et al.
Gastroenterology|April 21, 2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.
Gastroenterology|December 13, 2000
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study GroupS Schreiber, R N Fedorak, O H Nielsen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 1998
Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1J H Cho, D L Nicolae, L H Gold, et al.
Nature|June 1, 2001
A frameshift mutation in NOD2 associated with susceptibility to Crohn's diseaseY Ogura, D K Bonen, N Inohara, et al.
Pageof 15

Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
The New England Journal of Medicine|May 6, 1999
Infliximab for the treatment of fistulas in patients with Crohn's diseaseD H Present, P Rutgeerts, S Targan, et al.
Gastroenterology|October 31, 1998
American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12S R Brant, Y Fu, C T Fields, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2005
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's diseaseB G Feagan, W J Sandborn, J P Baker, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2017
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitisJ-F Colombel, W J Sandborn, W Reinisch, et al.
Gut|April 1, 1997
Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trialR I Breuer, K H Soergel, B A Lashner, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trialW J Sandborn, B E Sands, D C Wolf, et al.
Gastroenterology|April 21, 2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.
Gastroenterology|December 13, 2000
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study GroupS Schreiber, R N Fedorak, O H Nielsen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 1998
Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1J H Cho, D L Nicolae, L H Gold, et al.
Nature|June 1, 2001
A frameshift mutation in NOD2 associated with susceptibility to Crohn's diseaseY Ogura, D K Bonen, N Inohara, et al.
Pageof 15